Surgalign (Nasdaq:SRGA) announced today that it released its HOLO AI Insights for use in neurovascular research.
Deerfield, Illinois-based Surgalign initially launched HOLO AI Insights for spine imaging in March 2023. It enables customers, partners and clinical researchers to utilize the HOLO AI portfolio. The system features a secure, highly scalable cloud platform for the automated analysis of medical images.
HOLO AI utilizes convolutional neural network technology. It automatically segments medical images, measures anatomic structures, automates pedicle screw planning and performs other tasks.
The latest release brings HOLO AI to neurovascular research. The system can analyze large sets of cranial MRI images and automatically identify 16 different structures. It can also aggregate the data for the user into configurable graphical and file formats. Insights generated this way can provide multiple applications in population health, clinical research and — potentially — patient care.
Surgalign partnered with Dr. Brian Jankowitz to conduct neurovascular research with HOLO AI Insights. Jankowitz, a neurosurgery specialist, brings extensive experience in neurocritical care disorders. His affiliations include the medical facilities Hospital of the University of Pennsylvania and Cooper University Hospital.
“It’s an honor to partner with Dr. Jankowitz with a shared goal of advancing technology utilized by neuroanatomy researchers,” said Terry Rich, president and CEO of Surgalign. “Collecting patient-specific medical information from multiple sites to generate population-level reports using AI technology holds tremendous promise to improve our knowledge of the brain.
“We believe processing larger volumes of data is an invaluable step to generate reference information to help medical professionals as we continue to look for new ways to leverage our AI portfolio.”